Drugs that contain Cabotegravir; Rilpivirine
1. List of Cabenuva Kit drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US8080551 | VIIV HLTHCARE | HIV inhibiting pyrimidines derivatives |
Apr, 2023
(a month from now) | |
| US7125879 | VIIV HLTHCARE | HIV inhibiting pyrimidines derivatives |
Apr, 2025
(2 years from now) | |
| US8410103 | VIIV HLTHCARE | (3S,11aR)-N-[2,4-difluorophenyl)methyl]-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydro[1,3]oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide useful as anti-HIV agent |
Apr, 2026
(3 years from now) | |
| US10927129 | VIIV HLTHCARE | N-[(2,4-difluorophenyl)methyl]-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydro[1,3] oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide having HIV integrase inhibitory activity |
Apr, 2026
(3 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11389447 | VIIV HLTHCARE | Aqueous suspensions of TMC278 |
Jun, 2027
(4 years from now) | |
| US11224597 | VIIV HLTHCARE | Pharmaceutical compositions |
Sep, 2031
(8 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Jan 21, 2026 |
| New Patient Population (NPP) | Mar 29, 2025 |
| New Dosing Schedule (D) | Jan 31, 2025 |
NCE-1 date: January, 2025
Market Authorisation Date: 21 January, 2021
Treatment: Treatment of hiv-1 infection in adults and adolescents 12 years of age and older and weighing at least 35 kg by monthly administration of rilpivirine suspension as part of combination therapy; Treatment of hiv infection in adults; Treatment of hiv-1 infection in adults to replace the current antiretroviral regimen in those who are virologically suppressed on a stable antiretroviral regimen with no history of treatment failure
Dosage: SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR
CABENUVA KIT family patents
67
United States
35
European Union
23
Japan
21
Hungary
21
Norway
16
Spain
14
Korea, Republic of
13
Slovenia
13
Denmark
12
Australia
12
Lithuania
11
Poland
11
Portugal
11
China
10
Brazil
9
Hong Kong
9
Israel
9
Mexico
8
Cyprus
8
EA
8
Croatia
8
Canada
8
Taiwan, Province of China
7
Luxembourg
6
Ukraine
6
South Africa
6
New Zealand
5
AP
4
Austria
4
Argentina
3
RS
3
Netherlands
3
Belgium
2
Morocco
2
Chile
2
Malaysia
2
Jordan
2
Singapore
2
ME
2
Costa Rica
2
Nicaragua
1
Viet Nam
1
Uruguay
1
Germany
1
OA
1
Egypt
1
Peru
1
Philippines
1
Panama
1
San Marino
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic